Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-27
2009-10-06
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S510000
Reexamination Certificate
active
07598290
ABSTRACT:
The invention relates to taxanes and to novel cytotoxic agents comprising taxanes and their therapeutic use as a result of delivering the taxanes to a specific cell population in a targeted fashion by chemically linking the taxane to a cell binding agent.
REFERENCES:
patent: 6589979 (2003-07-01), Bombardelli et al.
patent: 7186851 (2007-03-01), Baloglu
patent: 0617034 (1994-09-01), None
patent: 0617034 (1994-09-01), None
patent: 0138318 (2001-05-01), None
patent: 200138318 (2001-05-01), None
patent: 03097625 (2003-11-01), None
patent: 2003097625 (2003-11-01), None
patent: 2004013093 (2004-02-01), None
K. C. Nicolaou et al., “Chemical synthesis and biological evaluation of c-2 taxoids”, Journal of the American Chemical Society, vol. 117, No. 9, pp. 2409-2420, 1995.
Kim et al., “C-2 modified taxol Analogs with Improved Aqueous Solubility”, Bull. Korean Chem. Soc., vol. 20, No. 12, pp. 1389-1390, 1999.
Ojima Iwao, et al., “Tumor-specific novel taxoid-monoclonal antibody conjugates”, Journal of Medicinal Chemistry, vol. 45, No. 26, pp. 5620-5623, Dec. 19, 2002.
M. L. Miller, et al., “Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies”, Bioorganic & Medicinal Chemistry Letters, vol. 14, No. 15, pp. 4079-4082, Aug. 2, 2004.
M. L. Miller, et al., “Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery”, Journal of Medicinal Chemistry, vol. 47, No. 20, pp. 4802-4805, Sep. 23, 2004.
K. C. Nicolaou et al., “Chemical synthesis and biological evaluation of c-2 taxoids”, Journal of the American Chemical Society, vol. 117, No. 9, pp. 2409-2420, 1995.
Kim et al., “C-2 modified taxol Analogs with Improved Aqueous Solubility”, Bull. Korean Chem. Soc., vol. 20, No. 12, pp. 1389-1390, 1999.
Ojima Iwao, et al., “Tumor-specific novel taxoid-monoclonal antibody conjugates”, Journal of Medicinal Chemistry, vol. 45, No. 26, pp. 5620-5623, Dec. 19, 2002.
M. L. Miller, et al., “Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies”, Bioorganic & Medicinal Chemistry Letters, vol. 14, No. 15, pp. 4079-4082, Aug. 2, 2004.
M. L. Miller, et al., “Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery”, Journal of Medicinal Chemistry, vol. 47, No. 20, pp. 4802-4805, Sep. 23, 2004.
Baloglu Erkan
Chari Ravi V. J.
Miller Michael L.
Andres Janet L.
Covington Raymond
Immunogen Inc.
Sughrue & Mion, PLLC
LandOfFree
Cytotoxic agents comprising new C-2 modified taxanes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic agents comprising new C-2 modified taxanes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic agents comprising new C-2 modified taxanes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4121971